Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 498Rectal Neoplasms 268Colonic Neoplasms 219Pancreatic Neoplasms 190Stomach Neoplasms 183Esophageal Neoplasms 135Breast Neoplasms 119Neoplasm Metastasis 117Squamous Cell Carcinoma of Head and Neck 95Head and Neck Neoplasms 92Neoplasms 90Adenocarcinoma Of Esophagus 67Esophageal Squamous Cell Carcinoma 62Carcinoma, Hepatocellular 56Adenocarcinoma 40Nasopharyngeal Carcinoma 35Cholangiocarcinoma 33Biliary Tract Neoplasms 27Anus Neoplasms 26Gastrointestinal Neoplasms 25Carcinoma, Squamous Cell 25Carcinoma, Non-Small-Cell Lung 25Keratosis, Actinic 23Gallbladder Neoplasms 22Liver Neoplasms 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 20Bile Duct Neoplasms 19Ovarian Neoplasms 16Carcinoma 16

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Efficacy and Safety × Fluorouracil × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡